SCHEMBL2929142

SCHEMBL2929142

COc1cc(C(=O)N(C)C2CCN(C)C2)ccc1Nc1cncc(-c2cc3cc(Cl)ccc3[nH]2)n1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PYGL P06737 2/20 0.46
TTK P33981 4/20 0.44
CCNA2 P20248 3/20 0.44
CDK2 P24941 3/20 0.44
IGF1R P08069 1/20 0.40
MCHR1 Q99705 3/20 0.40
AURKB Q96GD4 1/20 0.37
TLR9 Q9NR96 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
PTK2 Q05397 4/20 0.36
HRH3 Q9Y5N1 2/20 0.36
HRH4 Q9H3N8 1/20 0.36
F10 P00742 1/20 0.35
JAK1 P23458 1/20 0.35
LRRK2 Q5S007 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2934965 0.95 PYGL (0.42) PYGLTTKCCNA2CDK2IGF1R
SCHEMBL2932839 0.94 TTK (0.46) PYGLTTKCCNA2CDK2IGF1R
SCHEMBL2927688 0.93 TTK (0.46) PYGLTTKCCNA2CDK2IGF1R
SCHEMBL2929194 0.92 TTK (0.45) PYGLTTKCCNA2CDK2IGF1R
SCHEMBL2932957 0.92 TTK (0.45) PYGLTTKCCNA2CDK2IGF1R
SCHEMBL2932619 0.91 TTK (0.46) TTKCCNA2CDK2IGF1RMCHR1
Trifluoroacetic Acid SCHEMBL2930408 0.90 TTK (0.43) PYGLTTKCCNA2CDK2IGF1R
SCHEMBL2929184 0.90 TTK (0.43) PYGLTTKCCNA2CDK2IGF1R
Trifluoroacetic Acid SCHEMBL2935933 0.89 CCNA2 (0.42) TTKCCNA2CDK2IGF1RTLR9
Trifluoroacetic Acid SCHEMBL2934774 0.89 TTK (0.42) TTKCCNA2CDK2IGF1RMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP claimed
EP-2044051-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (publ) (SE) 2009-04-08 EP claimed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US claimed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO claimed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 PYGL 495/4885TTK 266/4885CCNA2 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.